Oliver Pfaar, Hendrik Wolf, Rainer Reiber, André Knulst, Kirsten Sidenius, Mika J Mäkelä, Sverre Steinsvåg, Christer Janson, Leonard van der Zwan, Elena Uss, Peter Arvidsson, Kathrin Borchert, Helena Himmelhaus, Eike Wüstenberg
BACKGROUND: The SQ tree sublingual immunotherapy (SLIT)-tablet is authorised for treatment of allergic rhinoconjunctivitis with or without asthma in trees of the birch homologous group in 21 European countries. The primary objective of this study was to explore the safety in real-life. METHODS: In a prospective, non-interventional post-authorisation safety study (EUPAS31470), adverse events (AEs) and adverse drug reactions (ADRs) at first administration and follow-up visits, symptoms, medication use, and pollen food syndrome were recorded by physicians in 6 European countries during the first 4-6 months of treatment...
July 2024: Clinical and Translational Allergy